01 / Research review
Behind the synopsis.
An original review of the published evidence for Tesamorelin, with human findings separated from laboratory and animal research.
What the compound is
Tesamorelin is an analogue of growth-hormone-releasing hormone. Its medical development concerns stimulation of the growth-hormone axis and changes in visceral fat. The US Egrifta label concerns excess abdominal fat in adults with HIV-associated lipodystrophy; it explicitly distinguishes this indication from weight-loss management. The prescription formulation is not interchangeable with a separately supplied research vial. [5]
Anatomy / conceptual schematic
Location matters.
Two fat compartments, with different research meanings.
Subcutaneous fatBeneath the skin, outside the abdominal wall.
Visceral fatInside the abdomen, around internal organs. The trial’s measured endpoint.
Internal organsShown only to orient the illustration.
Simplified abdominal cross-section, not to scale. This is an anatomical explanation, not a before-and-after image or a simulation of treatment effects.
Visceral fat: the central clinical finding
A 2007 trial randomised 412 people with HIV and abdominal-fat accumulation for 26 weeks. Visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% with placebo. The measurement was visceral fat assessed by imaging, not total body-weight loss. The population was predominantly male. These details limit the way a result should be described on a general audience page. [1]
A separate 404-person trial examined six-month efficacy and a further six-month extension. Visceral-fat reductions were sustained in those continuing treatment, while the initial improvements were rapidly lost after switching to placebo. This argues against presenting the intervention as a permanent change after a finite course. The study also distinguished visceral from subcutaneous fat. [2]
Liver-fat research
A 2014 trial randomised 50 participants with HIV and abdominal-fat accumulation; 48 received study treatment. It found reductions in visceral and liver fat over six months. Early glucose changes and the small study size were relevant limitations. The investigators described the liver finding as preliminary and called for clarification of clinical importance. [3]
A 2019 study enrolled 61 people with HIV and fatty liver disease, with 60 receiving treatment. At twelve months, the estimated between-group absolute liver-fat effect was −4.1 percentage points, corresponding to a relative reduction of 37%. Absolute and relative changes describe different quantities. The study is relevant to this specific liver-disease population; it is not evidence of equivalent benefit in otherwise healthy adults seeking a flatter abdomen. [4]
Human medical context
Human trials used subcutaneous administration of a characterised investigational or prescription medicine with clinical monitoring. The US label provides a specific medical indication and formulation requirements. Neither the trial route nor a shared ingredient name establishes a way to use the linked research product. [5]
For an Australian audience, a US approval is background context and must not be presented as local authorisation for Leni’s product. The distinction between an ingredient, an approved finished medicine and an unverified listing remains essential.
Safety and interpretation
The US label identifies elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity and malignancy-related precautions. Contraindications include active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis. These are reasons that the clinical context includes assessment and monitoring. [5]
Trial averages can conceal clinically relevant individual changes. The six-month liver study illustrates this: early glucose effects and longer-term averages were not identical. [3] Research pages should therefore report the studied population, body-fat compartment, duration and safety findings together. The most defensible synopsis recognises the visceral-fat evidence while avoiding a broad promise of weight reduction, muscle gain or rejuvenation.
02 / Key studies
The evidence in detail.
| Study & design | Finding | How to read it |
|---|---|---|
| Pivotal trial · 2007Human RCT · n=412 · 26 weeks | Visceral fat: −15.2% versus +5.0% with placebo. [1] | HIV-associated abdominal-fat accumulation; not total weight loss. |
| Trial and extension · 2010Human RCT · n=404 · 12 months | Continued treatment sustained visceral-fat changes. [2] | Improvements were lost after withdrawal. |
| Liver and visceral fat · 2014Human RCT · 50 randomised | Reduced imaging-measured visceral and liver fat. [3] | Small preliminary study; early glucose effects. |
| HIV-associated fatty liver · 2019Human RCT · 61 enrolled | Liver-fat effect: −4.1 percentage points at 12 months. [4] | Population-specific result; absolute and relative effects differ. |
03 / Open questions
What is not established.
- Clinical findings cannot be generalised to all causes of abdominal fat.
- The reviewed evidence does not establish a general anti-ageing or athletic-performance indication.
- US prescription-product evidence does not establish approval or equivalence of Leni’s vial.
04 / Papers & sources
Go to the source.
Read the original papers below. Open-access full text is linked where available; publisher access may require a subscription. These summaries do not reproduce the papers.
-
01
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Reviewed: PubMed abstract.
-
02
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Reviewed: PubMed abstract.
-
03
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Reviewed: PubMed abstract + selected full-text results/discussion/limitations.
-
04
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
Reviewed: PubMed abstract + selected full-text results/discussion/limitations.
-
05
Egrifta WR (tesamorelin): US prescribing information
Reviewed: Official source / product record.
How this page was researched
This is a targeted narrative review, not a systematic review or meta-analysis. Searches used compound names and aliases with terms for clinical trials, mechanisms, safety and specific research outcomes. Primary papers, PubMed records, selected open-access full-text sections, trial registries and official product or regulator documents were prioritised. Each source records what was inspected. Negative, mixed and small-study findings are retained. No claim is made that every publication has been captured.
Findings apply to the intervention and population studied. Evidence for a related molecule, another route or an approved medicine does not validate the Leni listing. The page has not been independently clinically or legally reviewed.
Related product listings and multipacks (4)
Multipacks change the item count, not the research evidence. Product-page names and specifications were captured from the live catalogue on 11 October 2026.